Lutathera Treatment

Since September 2022, we have introduced nuclear medicine treatment using Lutathera (generic name: Lutetium Oxodotreotide) for neuroendocrine tumors (NEN). This provides a new treatment option in addition to existing surgeries and chemotherapy.

Lutathera is a form of targeted radiotherapy administered intravenously. It contains a radioactive isotope (RI) that specifically targets and internally attacks tumor cells. Upon administration, Lutathera accumulates in the tumor cells and emits beta rays to destroy them.